AndrewLGilmanMD

PubMed

• 13 citations
  Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group.
  Ami V Desai, Andrew L Gilman, Mehmet Fevzi Ozkaynak, Arlene Naranjo, Wendy B London
  Journal of Clinical Oncology. 2022-12-10
• 101 citations
  Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.
  Alice L. Yu, Andrew L. Gilman, M. Fevzi Ozkaynak, Arlene Naranjo, Mitchell B. Diccianni
  Clinical Cancer Research. 2021-04-15
• 10 citations
  Donor lymphocyte infusion and methotrexate for immune recovery after T-cell depleted haploidentical transplantation.
  Andrew L. Gilman, Wing Leung, Morton J. Cowan, Mark Cannon, Stacy Epstein
  American Journal of Hematology. 2018-02-01

Journal Articles

• Interleukin-2-induced graft-versus-leukemia for the treatment of AML in a BRCA2 Fanconi Anemia patient  
  Yeo CJ, Gilman AL, J Pediatr Hematol Oncol, 1/1/2014
• Haploidentical Related Donor Hematopoietic Cell Transplantation in Children Using Megadoses of CliniMACS-selected CD34+ Cells and a Fixed CD3+ Dose  
  Dvorak CC, Gilman AL, Horn B, Oon C-Y, Dunn EA, Baxter-Lowe LA, Cowan MJ, Bone Marrow Transplantation, 1/1/2013
• Adoptive immunotherapy with CMV-specific T cytotoxic T lymphocytes for stem cell transplant patients with refractory CMV infections  
  Bao L, Cowan MJ, Dunham K, Horn B, McGuirk J, Gilman A, Lucas KG, J Immunother, 1/1/2012
• Early and Late Extensive Chronic Graft-Versus-Host Disease (cGVHD) in Children is Characterized by Different Th1/Th2 Cytokine Profiles: Findings of the Children’s Onco...  
  Rozmus J, Schultz KR, Wynne K, Kariminia A, Satyanarayana, Krailo MD, Grupp SA, Gilman AL, Goldman FD, Biology of Blood and Marrow Transplantation, 1/1/2011
• Chimeric Anti-GD2 Antibody with GM-CSF, IL2 and 13-cis-Retinoic Acid for High-risk Neuroblastoma: A Children’s Oncology Group (COG) Phase 3 Study  
  Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A,..., N Engl J Med, 1/1/2010
• Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: A Pediatric Blood and Marrow Transplant Consortium Study  
  Jacobsohn DA, Gilman AL, Rademaker A, Browning B, Grimley M, Lehmann L, Nemecek ER, Thormann K, Schultz KR, Vogelsang GB, Blood, 1/1/2009
• Clinical and immunological outcomes following haplocompatible donor lymphocyte infusions  
  Dvorak CC, Gilman AL, Horn B, Jaroscak J, Dunn EA, Baxter-Lowe LA, Cowan MJ, Bone Marrow Transplant, 1/1/2009
• Myeloablative chemotherapy with autologous stem cell rescue for Ewing sarcoma  
  Gilman AL, Oesterheld J, Bone Marrow Transplantation, 1/1/2008
• Infliximab for GVHD therapy in children  
  Sleight BS, Chan KW, Braun TM, Serrano A, Gilman A, Bone Marrow Transplantation, 1/1/2007
• Diagnosis and Treatment of Chronic Graft-Versus-Host Disease  
  Gilman AL and Serody J, Semin Hematol, 1/1/2006
• Cardiac Manifestations of Graft-Versus-Host Disease  
  Rackley C, Schultz KR, Goldman FD, Chan KW, Serrano A, Hulse JE, Gilman AL, Biol Blood Marrow Transplant, 1/1/2005
• Differential Effects of granulocyte colony stimulating factor on marrow and blood-derived hematopoietic and immune cell populations in healthy human donors  
  Shier LR, Schultz KR, Imren S, Regan J, Issekutz A, Sadek I, Gilman A, Luo Z, Panzarella T, Eaves CJ, Couban S, Biology of Blood and Marrow Transplantation, 1/1/2004
• Effect of in vivo lymphocyte-depleting strategies on development of lymphoproliferative disorders in children post allogeneic bone marrow transplantation  
  Lynch BA, Vasef MA, Comito M, Gilman AL, Lee N, Ritchie J, Rumelhart S, Holida M, Goldman F, Bone Marrow Transplantation, 1/1/2003
• Evaluation for synergistic suppression of T cell responses to minor histocompatibility antigens by chloroquine in combination with tacrolimus and a rapamycin derivativ...  
  Hsaio C, Su WN, Forooghian F, Bader S, Rempel J, Hayglass KT, Gilman A, Schultz KR, Bone Marrow Transplantation, 1/1/2002
• Treatment of chronic GVHD  
  Gilman AL, Schultz KR, Bone Marrow Transplantation, 1/1/2000
• Hydroxychloroquine for the treatment of chronic graft-versus-host disease  
  Gilman AL, Chan KW, Mogul M, Morris, C, Goldman F, Boyer M, Cirenza M, Mazumder A, Cahill R, Schultz K, Biology of Blood and Marrow Transplantation, 1/1/2000
• Complete heart block in association with graft-versus-host disease  
  Gilman AL, Kooy NW, Atkins D, Rumelhart S, Holida M, Lee N, Goldman F, Bone Marrow Transplantation, 1/1/1998
• The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease  
  Schultz KR, Gilman AL, Leukemia and Lymphoma, 1/1/1997
• The effect of hydroxychloroquine on alloreactivity and its potential use for graft-versus-host disease  
  Gilman AL, Beams F, Tefft M, Mazumder A, Bone Marrow Transplant, 1/1/1996
• HLA-B14 subtypes and their influence on allorecognition  
  Gilman AL, Auger J, Terry L, Flomenberg N, Baxter-Lowe LA, Tissue Antigens, 1/1/1996
• A novel hereditary macrothrombocytopenia  
  Gilman AL, Sloand E, White JG, Sacher R, Journal of Pediatric Hematology/Oncology, 1/1/1995
• Pyoderma gangrenosum as a manifestation of leukemia in childhood  
  Gilman, AL, Cohen BA, Urbach AH, Blatt J, Pediatrics, 1/1/1988
• Join now to see all

Abstracts/Posters

• A Comprehensive Safety Trial of Chimeric Antibody 14.18 with GM-CSF, IL-2 and Isotretinoin (ImmRx) in High-Risk Neuroblastoma Patients Following Myeloablative Therapy:...
  Ozkaynak MF, Gilman AL, Yu AL, London WB, Sondel PM, Smith M, Seeger R, Reynolds CP, Maris JM, Park JR, American Society of Clinical Oncology Meeting, 5/1/2014
• CD34-selected, T cell-depleted alternative donor stem cell transplantation for pediatric non-malignant diseases
  Eckrich MJ, Epstein S, Barnhart C, Oesterheld J, Grochowski D, Fuchs T, Cannon M, Lacaria M, Teplick A, Gilman A, Second Annual Pediatric Blood and Marrow Transplant Consortium at American Society of Pediatric Hematology/Oncology: New Frontiers in Allogeneic Stem Cell Transplant, 5/1/2014
• CD34-selected, T cell-depleted alternative donor stem cell transplantation for children
  Gilman A, Eckrich M, Epstein S, Barnhart C, Oesterheld J, Grochowski D, Fukes T, Lacaria M, Cannon M, American Society of Hematology, 55th Annual Meeting, 12/1/2013
• Allogeneic Hematopoietic cell transplantation is effective in patients with advanced systemic mastocytosis: A multicenter retrospective analysis
  Ustun C, Reiter A, Scott BL, Nakamura R, Gandhi D, Kreil S, Shanley R, Hogan WJ, Perales MA, Shore TB, Baurmann H, Stuart RK, Gruhn B, Doubek M, Hsu JW, Tholouli E, Gr..., American Society of Hematology, 55th Annual Meeting, 12/1/2013
• CD34-selected, T cell-depleted alternative donor stem cell transplantation for pediatric sickle cell disease
  Eckrich MJ, Epstein S, Barnhart C, Shah K, Oesterheld J, Gilman A, American Society of Pediatric Hematology/Oncology, 26th Annual Meeting, 4/1/2013
• Correction of Signal Transduction and Activator of Transcription 3 (STAT3) Function in an Adolescent with Autosomal Dominant Hyper-IgE Syndrome (AD-HIES) Following Hem...
  Gallagher JL, Gilman AL, Torgenson TR, Patel NC, American Academy of Allergy Asthma and Immunology Annual Meeting, 2/1/2013
• The Effect of Transplant Center Characteristics On Survival After Pediatric Hematopoietic Cell Transplantation
  Eckrich MJ, Le-Rademacher J, Rizzo JD, Baker KS, Bhatla D, Buchbinder DK, Cooke KR, Duerst R, Gilman A, Frangoul H, Kapoor N, Kernan NA, Verneris M, Eapen M, American Society of Hematology 54th Annual Meeting, 12/1/2012
• A Case Of Vibrio alginolyticus Septicemia In A Pediatric Transplant Patient
  Ahmed A, Gilman AL, Barnhart C, Grodman HM, Sautter RL, American Society for Microbiology meeting, 5/1/2011
• Phase III Randomized Trial of the Chimeric Anti-GD2 Antibody ch14.18 with GM-CSF and IL-2 as Immunotherapy following Dose Intensive Chemotherapy for High-risk Neurobla...
  Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman S, Chen HX, Matthay KK, Cohn SL, Maris JM, Sondel P, American Society of Clinical Oncology Meeting, 5/1/2009
• Multi-Institutional Phase II Study of Pentostatin for the Treatment of Refractory Chronic GVHD (cGVHD) in Children: A Pediatric Blood and Marrow Transplant Consortium ...
  Jacobsohn DA, Browning B, Gilman A, Lehmann L, Nemecek E, Thormann K, Vogelsang GB, American Society of Blood and Marrow Transplantation Meeting, 2/1/2008
• Duration of Hospitalization in the First 100 Days Following Reduced Intensity Conditioning for Non-malignant Disorder Transplants in Children
  Witty S, Barnes Y, Yu L, Gilman A, Nieder M, Adams R, Dalal J, Pulsipher M, Kamani N, Grimley M, Shenoy S, American Society of Blood and Marrow Transplantation Meeting, 2/1/2008
• Megadose CD34-selected Haplocompatible Donor Stem Cell Transplantation in Children
  Sleight BS, Cowan MJ, McGuirk J, Horn B, Jaroscak J, Gilman A, American Society of Hematology Meeting, Forty-eighth Annual Meeting, 12/1/2006
• Designing FISH Assays for Cancer Patients With "Un-FISHable" Abnormalities: Hypermetaphase + Commercially Available Probes
  Rao KW, Kaiser-Rogers K, Nandi K, Vigil M, Wiley J, Betz S, Gilman A, Annual Clinical Genetics Meeting, 3/1/2006
• Evaluation for Th1 and Th2 shifts in Newly Diagnosed Pediatric Chronic Graft-versus-Host Disease (GvHD)
  Schultz KR, Goldman F, Aslanian S, Shimizu H, Krailo M, Wall D, Gilman A, American Society of Blood and Marrow Transplantation Meeting, 2/1/2006
• Eosinophilia, positive ANA, and hypergammaglobulinemia at presentation of extensive chronic GVHD (cGVHD) in children: a Children’s Oncology Group study
  Jacobsohn DA, Schultz KR, Goldman F, Wall DA, Krailo M, Chen Z, Lipton JM, Sanders JE, Gilman AL, American Society of Hematology Meeting, Forty-seventh Annual Meeting, 12/1/2005
• Increased TLR9 Responses in B cells at the Onset of Chronic GVHD
  She K, Aslanian S, Shimizu H, Gilman AL, Schultz KR, First Annual International Scientific Conference on Pediatric Blood & Marrow Transplantation Meeting, 10/1/2005
• An Exaggerated B Cell CpG Response in Human Chronic Graft-Versus-Host Disease: A Potential Mechanism and Biomarker for Diagnosis of Chronic GVHD
  She K, Gilman AL, Schultz KR, American Society of Hematology Meeting, Forty-sixth Annual Meeting, 12/1/2004
• Fludarabine (FLU) containing preparative regimens for hematopoietic stem cell transplantation (HSCT) in severe combined immune deficiency syndromes (SCIDS): Interim re...
  Kamani N, Infante A, DeSantes K, Gilman A, Goyal R, Pulsipher M, Wall D, American Society of Hematology Meeting, Forty-fifth Annual Meeting, 12/1/2003
• Ex vivo T-cell depletion for graft-versus-host disease prophylaxis in related haplo-identical allogeneic stem cell transplant recipients
  McGuirk JP, Dix SP, Greenfield D, Belt RJ, Picken S, Meagher R, Jensen K, Barnhart CS, Gilman A, American Society of Hematology Meeting, Forty-second Annual Meeting, 12/1/2000
• Dual cycle high-dose chemotherapy with stem cell rescue for recurrent brain tumors
  Gilman A, Bunin N, Levine J, Joyce M, Anderson P, Bendel A, Pietryga D, Anderson R, Goldman F, Rozans M, Sambrano J, Kadota R, Hetherington M, American Society Pediatric Hematology/Oncology, Thirteenth Annual Meeting, 9/1/2000
• Hydroxychloroquine for the treatment of chronic graft-versus-host disease
  Gilman A, Chan KW, Mogul M, Morris C, Goldman F, Boyer M, Cirenza E, Mazumder A, Cahill R, Frankel S, Schultz K, American Society for Blood and Marrow Transplantation Meeting, 3/1/1999
• Hydroxchloroquine inhibits calcium flux in T cells and augments the immunosuppressive properties of cyclosporine A
  Goldman FD, Gilman A, Hollenback C, Kato R, Rawlings D, American Society of Hematology Meeting, Fortieth Annual Meeting, 12/1/1998
• Effects of hydroxchloroquine on T-cell antigen receptor signaling
  Goldman FD, Hollenback C, Gilman A, American Society of Hematology Meeting, Thirty-ninth Annual meeting, 12/1/1997
• An immunocytologic (ICC) assay for detecting Ewing's sarcoma cells in marrow and stem cell products
  Moss TJ, Ramsay N, Bostrom B, Gilman AL, American Society of Hematology Meeting, Thirty-eighth Annual Meeting, 12/1/1996
• Prophylactic donor lymphocyte infusions in children undergoing T cell depleted BMT from unrelated (UR) or mismatched (MR) donors
  Trigg ME, Goldman F, Gilman AL, Rumelhart S, Holida M, Lee N, International Society for Experimental Hematology Meeting, 8/1/1996
• Join now to see all

Lectures

• Graft Engineering – Building a Better Bone Marrow Transplant 
  Charlotte, NC - 3/1/2013
• Role of Cytogenetics and Molecular Genetics in BMT 
  11/1/2008
• Pulmonary Complications of Bone Marrow Transplantation 
  4/1/2007
• Complications of Bone Marrow Transplantation 
  11/1/2006
• Haploidentical Donor Stem Cell Transplantation 
  Chapel Hill, NC - 9/1/2006
• Recent Advances in Stem Cell Transplantation 
  8/1/2006
• Molecular monitoring in Bone Marrow Transplantation 
  8/1/2005
• Bone Marrow Transplantation for Primary Immunodeficiencies 
  4/1/2003
• Bone Marrow Transplantation - Past, Present, and Future 
  Kansas City, MO - 6/1/1999
• Transplantation Immunology 
  5/1/1999
• Bone Marrow Transplantation 
  7/1/1998
• Hydroxychloroquine for the treatment of GVHD 
  11/1/1996
• Lymphocytes and GVHD: Bench to bedside 
  Iowa City, IA - 4/1/1996
• New approaches for recurrent brain tumors and solid tumors 
  11/1/1995
• Join now to see all